Virology and Immunology in Multiple Sclerosis: Rationale for Therapy: Proceedings of the International Congress, Milan, December 9–11, 1986

Front Matter....Pages I-VIII
Front Matter....Pages 1-1
Immunocyte Abnormalities in Multiple Sclerosis....Pages 3-7
Different T-Cell Response to Myelin Basic Protein in Multiple Sclerosis Patients and in Healthy Subjects....Pages 8-12
Glial Cells and Products of Activated Inflammatory Cells: Implications for Pathogenesis and Treatment of Multiple Sclerosis....Pages 13-20
Intrathecal IgG Synthesis in Multiple Sclerosis: Correlation with Clinical Parameters....Pages 21-31
Loss of Reliability and Sensitivity of Agarose Isoelectric Focusing and Quantitative Formulae in the Detection of Intrathecally Synthesized IgG in the Presence of Blood-Brain Barrier Damage....Pages 32-34
Lymphocyte Subpopulations as Markers of Disease Activity in Multiple Sclerosis*....Pages 35-42
Serological Studies of Patients with Multiple Sclerosis, controls, and Patients with Other Neurological Diseases: Antibodies to HTLV-I, HTLV-II, HIV, and STLV-III....Pages 43-50
Correlation of Oligoclonal IgG Bands and Viral Antibodies in Twins with Multiple Sclerosis....Pages 51-54
Detection of HLA Class II Restriction Fragment Length Polymorphisms in Multiple Sclerosis Using Pooled DNA Samples....Pages 55-63
HLA Studies in the Multiple Sclerosis Population....Pages 65-69
Multiple Sclerosis: Phenotypic Immunogenetic Markers and Nucleic Acid Biochemistry....Pages 70-77
Genetics in Multiple Sclerosis — with Special Emphasis on Twin Studies....Pages 78-83
Front Matter....Pages 85-85
Risk Factors, Course, and Prognosis of Multiple Selerosis....Pages 87-109
Epidemiological Studies of Multiple Sclerosis in Western Norway: Possible Factors in Etiology and Prognosis....Pages 110-114
Multiple Sclerosis: Stochastic Models of Prognosis....Pages 115-124
Studies of the Natural History of Multiple Sclerosis....Pages 125-132
Space-Time Aggregation in a Small Village in Italy: Buti (Pisa)....Pages 133-140
Immunotherapy in Multiple Sclerosis: Arguments for Early Treatment....Pages 141-146
Selective Immunosuppression in Multiple Sclerosis....Pages 147-152
Use of Azathioprine in Multiple Sclerosis....Pages 153-161
Front Matter....Pages 85-85
Immunosuppression with Azathioprine in Multiple Sclerosis....Pages 162-171
Multiple Sclerosis: Preliminary Reports of a Therapeutical Trial and Magnetic Resonance Imaging Correlates....Pages 172-178
New Trends for Treatment in Multiple Sclerosis....Pages 179-185
Front Matter....Pages 187-187
Limitations of Peroxidase Staining in the Detection of CSF IgA Separated by Agarose Isoelectric Focusing....Pages 189-192
Failure to Detect Anti-HTLV-III Antibodies in Serum and CSF of 84 Neurological Patients....Pages 193-195
Absence of Serum HTLV-I and -III Antibodies in Multiple Sclerosis Patients....Pages 196-197
Antigen Histocompatibility (HLA) in Multiple Sclerosis Patients from Gorski Kotar, Yugoslavia....Pages 198-200
Diagnostic and Predictive Value of Nonclinical Tests in Retrobulbar Optic Neuritis....Pages 201-204
Contribution of Magnetic Resonance Imaging in the Assessment of Multiple Sclerosis....Pages 205-207
Serial Evoked Potentials and Disease Progression in Multiple Sclerosis....Pages 208-213
Clinical and Immunological Findings After Treatment with Thymostimulin in Multiple Sclerosis....Pages 214-217
Treatment of Multiple Sclerosis with a Mega Dose of 6-Methylprednisolone....Pages 218-220
Long-Term Hyperbaric Oxygen in Chronic Progressive Multiple Sclerosis: A Placebo-Controlled Double-Blind Randomized Study with Evoked Potential Evaluation....Pages 221-224
Psychotherapy in Patients with Multiple Sclerosis....Pages 225-227
Cognitive Impairment in Multiple Sclerosis....Pages 228-230
Back Matter....Pages 231-232